Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) Net Margin (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Net Margin data on record, last reported at 43.98% in Q4 2025.

  • For Q4 2025, Net Margin fell 4109.0% year-over-year to 43.98%; the TTM value through Dec 2025 reached 55.08%, up 5601.0%, while the annual FY2025 figure was 55.08%, 5602.0% up from the prior year.
  • Net Margin reached 43.98% in Q4 2025 per TGTX's latest filing, down from 241.73% in the prior quarter.
  • Across five years, Net Margin topped out at 113643.75% in Q4 2022 and bottomed at 38948.94% in Q3 2022.
  • Average Net Margin over 5 years is 1936.63%, with a median of 37.35% recorded in 2023.
  • Peak YoY movement for Net Margin: soared 22771995bps in 2021, then crashed -11367446bps in 2023.
  • A 5-year view of Net Margin shows it stood at 4051.1% in 2021, then skyrocketed by 2905bps to 113643.75% in 2022, then plummeted by -100bps to 30.71% in 2023, then skyrocketed by 91bps to 2.89% in 2024, then plummeted by -1421bps to 43.98% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 43.98% in Q4 2025, 241.73% in Q3 2025, and 19.97% in Q2 2025.